1. Home
  2. BCAB vs FEAM Comparison

BCAB vs FEAM Comparison

Compare BCAB & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • FEAM
  • Stock Information
  • Founded
  • BCAB 2007
  • FEAM 2016
  • Country
  • BCAB United States
  • FEAM United States
  • Employees
  • BCAB N/A
  • FEAM N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • FEAM Major Chemicals
  • Sector
  • BCAB Health Care
  • FEAM Industrials
  • Exchange
  • BCAB Nasdaq
  • FEAM Nasdaq
  • Market Cap
  • BCAB 96.2M
  • FEAM 44.6M
  • IPO Year
  • BCAB 2020
  • FEAM N/A
  • Fundamental
  • Price
  • BCAB $2.08
  • FEAM $0.47
  • Analyst Decision
  • BCAB Strong Buy
  • FEAM Buy
  • Analyst Count
  • BCAB 2
  • FEAM 4
  • Target Price
  • BCAB $6.00
  • FEAM $4.19
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • FEAM 153.2K
  • Earning Date
  • BCAB 11-08-2024
  • FEAM 11-11-2024
  • Dividend Yield
  • BCAB N/A
  • FEAM N/A
  • EPS Growth
  • BCAB N/A
  • FEAM N/A
  • EPS
  • BCAB N/A
  • FEAM N/A
  • Revenue
  • BCAB N/A
  • FEAM N/A
  • Revenue This Year
  • BCAB N/A
  • FEAM N/A
  • Revenue Next Year
  • BCAB N/A
  • FEAM $1,117.19
  • P/E Ratio
  • BCAB N/A
  • FEAM N/A
  • Revenue Growth
  • BCAB N/A
  • FEAM N/A
  • 52 Week Low
  • BCAB $1.14
  • FEAM $0.40
  • 52 Week High
  • BCAB $4.02
  • FEAM $2.61
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • FEAM 38.57
  • Support Level
  • BCAB $1.87
  • FEAM $0.43
  • Resistance Level
  • BCAB $2.13
  • FEAM $0.57
  • Average True Range (ATR)
  • BCAB 0.12
  • FEAM 0.06
  • MACD
  • BCAB 0.00
  • FEAM -0.01
  • Stochastic Oscillator
  • BCAB 68.90
  • FEAM 26.20

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

Share on Social Networks: